Biogen Inc. stock underperforms Tuesday when compared to competitors
The stock's fall snapped a two-day winning streak.
Has Jim Cramer Lost Faith in Biogen Inc. (BIIB)’s Struggles with Alzheimer’s and MS Challenges?
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Biogen Inc. stock outperforms competitors despite losses on the day
This was the stock's second consecutive day of losses.
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Biogen Holds On, But Growth Slips Through Its Fingers
Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.
Biogen appoints Feire as Head of Business Development and External Innovation
Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...
Peering Into Biogen's Recent Short Interest
According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers. Did you know that ...
Royalty Pharma Announces Dividend Increase
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...
Beaten Down Biogen Stock Looks Attractive At Current Levels
The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.
Fintel on MSN6d
Piper Sandler Downgrades Biogen (BIIB)
Fintel reports that on January 2, 2025, Piper Sandler downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight to ...
Biogen Inc. (BIIB): Among the Cheap Healthcare Stocks to Buy Heading Into 2025
We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025. In this article, we are going to take ...
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
Piper Sandler downgraded Biogen Inc (NASDAQ:BIIB) from “overweight” to “neutral,” given a challenging transition period for the biotech firm. The brokerage hacked the price target from $315 of $138, ...